Moderna seeks U.S. authorization for COVID-19 vaccine booster
Reuters
Published Sep 01, 2021 05:52PM ET
Updated Sep 01, 2021 06:25PM ET
By Michael Erman and Manojna Maddipatla
(Reuters) -Moderna Inc on Wednesday asked the U.S. Food and Drug Administration (FDA) to allow the use of a third booster dose of its COVID-19 vaccine.
The FDA is considering booster shots of the Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) vaccine, but so far has only allowed people with weakened immune systems to receive third doses of either the Moderna (NASDAQ:MRNA) or Pfizer shots.
The agency said on Wednesday that a group of its advisers will meet to discuss Pfizer's booster shot application on Sept. 17, but it is not clear whether they will discuss Moderna's.
Moderna said it submitted initial data for the use of a 50-microgram booster dose of its two-shot vaccine. The original Moderna vaccine contains 100 micrograms of mRNA in each shot.
Recipients of the 50-microgram dose had robust antibody responses against the Delta variant, Moderna Chief Executive Stéphane Bancel said in a statement.
Although Moderna has said its COVID-19 vaccine was still about 93% effective 6 months after the second dose, it has observed that antibody levels had waned significantly at that point.
It said that nearly 350 participants of its original Phase II trial were given a third vaccine dose that generated a better immune response than what was seen after the second dose in its large Phase III clinical trial.
Moderna said the safety profile of the third dose was similar to that of the second dose.
The company said it expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world in the coming days.
Several countries are already offering or have plans to give booster doses to older citizens or people with weak immune systems as infections and hospitalization soar due to the highly contagious Delta variant of the virus and evidence of waning antibody levels in vaccinated people after six months.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.